Johnson & Johnson has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for BALVERSA ® ▼ (erdafitinib) as a monotherapy for the ...

Clinical annotation evaluates oncology guidelines, published research on molecular alterations within the same or different tumor types, functional implications, roles in the overall biological ...

These data provide clinical support that an FGFR3 inhibitor designed to be highly selective can deliver meaningful clinical ...

The drug has been approved as an oral monotherapy for adults with unresectable or metastatic cases of urothelial carcinoma (UC), the most common form of the disease, who are harbouring susceptible ...

Reported the first preliminary clinical case study of the IDE397 and Trodelvy combination in MTAP-deletion UC at ENA 2024, including a PR by RECIST 1.1 in a patient case report with a genetic ...

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health ...

TYRA-300 was generally well-tolerated, with no grade 4 or higher treatment-related adverse events reported. The ongoing SURF301 trial is enrolling patients with FGFR3-altered mUC and other solid ...

Quebec has hit the breaks on two major permanent resident pathways. Effective immediately, Quebec is no longer accepting applications for the Quebec Experience Program - Quebec Graduates (PEQ - ...

These results demonstrate that FOXG1 suppresses Fgfr3 gene expression and the MAPK/ERK pathway, and loss of Foxg1 results in an enhancement of this pro-gliogenic pathway. The decline in nuclear FOXG1 ...